Appointment of Nominated Adviser /Corporate Broker

This is a routine adviser switch, not a signal of business momentum or financial change.

What the company is saying

Creo Medical Group plc is telling investors that it remains focused on developing and commercialising minimally invasive electrosurgical devices, with its proprietary CROMA platform powered by Kamaptive technology at the core of its offering. The company claims its technology can optimise surgical capability and improve patient outcomes, positioning itself as an innovator in the medical device space. The announcement highlights the appointment of Shore Capital and Corporate Limited as Nominated Adviser and Shore Capital Stockbrokers Limited as sole Corporate Broker, effective immediately, as the headline event. The language used is confident but measured, with phrases like 'the Directors believe' and 'the Company's vision' framing the technology as transformative, though these are not backed by hard evidence in this release. The announcement is silent on financial performance, operational milestones, or commercial traction, omitting any discussion of revenue, profitability, or adoption rates. No notable individuals with external institutional roles are identified as participating in this event; the only named individuals are company officers and PR contacts, which does not add external validation. The communication style is standard for a UK-listed healthcare company, focusing on regulatory compliance and technology narrative rather than investor excitement. There is no notable shift in messaging compared to prior communications, as no historical context is provided, but the tone and content are consistent with a routine corporate update rather than a strategic inflection point.

What the data suggests

The only concrete data disclosed is the appointment of new advisers and brokers, effective 23 June 2026, with no financial or operational metrics provided. There are no figures for revenue, profit, cash position, R&D spend, or any other financial indicator, making it impossible to assess the company's financial trajectory or health. The claims about the CROMA platform and Kamaptive technology are entirely qualitative, with no supporting clinical data, adoption statistics, or market penetration figures. There is no reference to prior targets, guidance, or whether any milestones have been met or missed, leaving investors with no basis for evaluating progress. The absence of financial disclosures is notable and limits the ability to compare this period to previous ones or to competitors. An independent analyst, looking only at the numbers (or lack thereof), would conclude that this announcement provides no evidence of business momentum, financial improvement, or operational achievement. The only verifiable facts are the change in corporate advisers and the continued existence of the company's technology narrative. The gap between what is claimed (transformative technology, improved outcomes) and what is evidenced (none) is wide, and the quality of disclosure is poor for any investor seeking to make a data-driven decision.

Analysis

The announcement is primarily a factual disclosure of new corporate adviser and broker appointments, which is supported by immediate and verifiable details. However, the narrative includes several aspirational and promotional statements about the company's technology and its potential impact, without providing any numerical evidence, clinical data, or operational milestones to substantiate these claims. The forward-looking statements are limited in number but use language such as 'vision', 'believe', and 'can impact', which are not backed by measurable outcomes. There is no mention of financial results, revenue, or concrete progress, and no timeline is given for when the stated benefits might be realised. The capital intensity flag is set to false, as there is no disclosure of a large capital outlay or investment in this announcement. Overall, the gap between narrative and evidence is moderate, with some inflated language but no egregious overstatement.

Risk flags

• ●Operational risk is high because the company is in the development and commercialisation phase for complex medical devices, which historically involves regulatory hurdles, clinical validation, and unpredictable timelines. The announcement provides no evidence of regulatory approvals, clinical trial progress, or commercial adoption.
• ●Financial disclosure risk is acute, as the announcement omits all financial data—no revenue, cash position, burn rate, or funding status is provided. This lack of transparency makes it impossible for investors to assess solvency, runway, or capital needs.
• ●Execution risk is significant due to the forward-looking nature of the claims about technology impact and patient outcomes, none of which are supported by clinical or commercial data. The gap between aspiration and evidence is wide, increasing the risk that stated goals may not be realised.
• ●Pattern-based risk is present because the company relies on promotional language ('vision', 'believe', 'can impact') without providing measurable milestones or outcomes. This pattern is often associated with early-stage or struggling companies seeking to maintain investor interest without substantive progress.
• ●Timeline risk is high, as there are no disclosed milestones or timeframes for when the purported benefits of the technology might be realised. Investors face the risk of indefinite delays or non-delivery.
• ●Disclosure risk is elevated by the omission of any discussion of operational or financial performance, which could indicate underlying issues or simply a lack of progress worth reporting. Either scenario is negative for investor confidence.
• ●Capital intensity risk is flagged by the company's stated focus on developing and commercialising a suite of medical devices, which typically requires significant ongoing investment. Without financial data, it is unclear how these efforts are being funded or sustained.
• ●Geographic risk is moderate, as the company is based in the United Kingdom, but there is no information about regulatory status or market access in other jurisdictions, which could limit growth or expose the company to additional compliance challenges.

Bottom line

For investors, this announcement is a routine change of corporate adviser and broker, not a signal of operational or financial progress. The company's narrative about transformative technology and improved patient outcomes is entirely aspirational in this context, with no supporting data or milestones disclosed. No external institutional figures are involved in this event, so there is no added validation or implied endorsement from the capital markets. To change this assessment, the company would need to disclose concrete financial results, clinical outcomes, regulatory milestones, or commercial adoption figures. Investors should watch for the next reporting period to see if any of these metrics are provided, particularly revenue, cash position, and evidence of market traction for the CROMA platform. This announcement should be weighted as a compliance update rather than a catalyst for investment action; it is worth monitoring only to the extent that future disclosures provide substantive evidence of progress. The single most important takeaway is that, absent hard data, the company's claims remain unproven and should not be relied upon for investment decisions.

Announcement summary

(AIM: CREO) Creo Medical Group plc announced the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as its sole Corporate Broker with immediate effect. The company is focused on the development and commercialisation of minimally invasive electrosurgical devices for pre-cancer and cancer patients. Creo Medical Group plc has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures. Shore Capital and Corporate Limited and Shore Capital Stockbrokers Limited are named as the new Nominated Adviser and Corporate Broker, respectively. The announcement was made on 23 June 2026.

Disagree with this article?